

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

# **WHO Expert Committee on Biological Standardization**

---

Thirty-seventh Report

World Health Organization  
Technical Report Series  
760



World Health Organization, Geneva 1987

ISBN 92 4 120760 4

© World Health Organization 1987

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

ISSN 0512-3054

PRINTED IN SWITZERLAND

87/7303 - Schüler S.A. - 6500

# CONTENTS

	Page
<b>General</b>	
The work of the International Laboratories for Biological Standards and of the Committee.....	9
Rabies vaccines.....	11
Hepatitis B vaccines .....	11
Vaccine quality .....	11
Substrates for production of biologicals.....	12
Safety of blood and blood products .....	12
Guidelines for the preparation and establishment of international and other standards and reference reagents for biological substances.....	12
Implications of heterogeneity of the active constituents in an international standard .....	13
International units, mass, and moles .....	15
Suitability of standards for different types of assay.....	15
Numerical order of international standards.....	16
Enzymes.....	16
Future meetings.....	16
 <b>SUBSTANCES</b> 	
<b>Antibiotics</b>	
1. Kanamycin.....	17
2. Netilmicin.....	17
3. Teicoplanin .....	17
 <b>Antibodies</b>	
4. Anti-rabies serum, equine, and anti-rabies immunoglobulin.....	18
5. Anti-toxoplasma IgM serum.....	18
6. Tetanus immunoglobulin .....	18
 <b>Antigens</b>	
7. Birch pollen extract.....	19
8. Dog ( <i>Canis domesticus</i> ) hair and dander extract.....	19
9. Other allergens.....	19
10. Purified protein derivative (PPD) of bovine tuberculin.....	20
 <b>Blood products and related substances</b>	
11. Anti-D (anti-Rh <sub>o</sub> ) complete blood-typing serum (chemically modified)	20
12. Human blood coagulation factors II, VII, IX, and X .....	21
13. Human C-reactive protein .....	21
14. Low molecular weight heparin .....	22
	3

**Endocrinological and related substances**

15. Human atrial natriuretic factor 99–126 .....	22
16. Chorionic gonadotrophin .....	23
17. Salmon calcitonin .....	23
18. Elcatonin .....	24
19. Follicle stimulating hormone .....	24
20. Human growth hormone .....	25
21. Insulins .....	25
22. Human insulin C-peptide .....	26
23. Interleukin-1 .....	26
24. Estrogen receptors .....	27
25. Parathyroid hormone, bovine, for bioassay .....	27
26. Bovine and porcine proinsulins .....	27
27. Human proinsulin .....	28
28. Prolactin .....	28
29. Somatomedin C .....	28

**Miscellaneous**

30. Apolipoproteins .....	29
31. Endotoxin .....	29
32. International reference reagent of hepatitis B vaccine (plasma-derived) .....	29
33. Human reference sera for antibodies to human immunodeficiency virus .....	30
34. Mumps international reference reagents .....	31
35. Rubella virus serum and rubella virus M-33 strain .....	31

**REQUIREMENTS FOR BIOLOGICAL SUBSTANCES**

36. Requirements for diphtheria toxoid, pertussis vaccine, tetanus toxoid, and combined vaccines .....	32
37. Requirements for hepatitis B vaccines made by recombinant DNA techniques in yeast .....	32
38. Requirements for mumps vaccine (live) .....	33
39. Requirements for poliomyelitis vaccine (oral) .....	34
40. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines .....	34

**ANNEXES**

Annex 1. Procedure for evaluating the acceptability in principle of vaccines proposed to United Nations agencies for use in immunization programmes .....	35
Annex 2. Model certificate for the release of vaccines acquired by United Nations agencies .....	38
Annex 3. Guidelines for the preparation and establishment of international and other standards and reference reagents for biological substances .....	39
Annex 4. Requirements for diphtheria toxoid, pertussis vaccine, tetanus toxoid, and combined vaccines (Addendum 1986) .....	82

Annex 5. Report of a WHO meeting on hepatitis B vaccines produced by recombinant DNA techniques .....	87
Annex 6. Requirements for hepatitis B vaccines made by recombinant DNA techniques in yeast .....	106
Annex 7. Requirements for mumps vaccine (live) .....	139
Annex 8. Requirements for poliomyelitis vaccine (oral) (Addendum 1986)...	165
Annex 9. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines .....	167
Annex 10. Biological substances: international standards, reference preparations, and reference reagents .....	195
Annex 11. Requirements for biological substances and other sets of recommendations .....	199

## WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 1-8 December 1986

### *Members*

- Professor T. Bektimirov, Director, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, USSR Ministry of Health, Moscow, USSR
- Dr J. Furesz, Director, Bureau of Biologics, Drugs Directorate, Ottawa, Ontario, Canada (*Rapporteur*)
- Dr M.C. Hardegree, Director, Division of Bacterial Products, Office of Biologics Research and Review, Center for Drugs and Biologics, Food and Drug Administration, Bethesda, MD, USA (*Chairwoman*)
- Dr S.R. Hollan, Director, National Institute of Haematology and Blood Transfusion, Budapest, Hungary
- Dr H. Mirchamsy, Associate Director, Razi State Institute of Sera and Vaccines, Teheran, Islamic Republic of Iran (*Vice-Chairman*)
- Dr R. Netter, Director-General, National Laboratory of Health, Paris, France
- Dr A. Oya, Director, Department of Virology and Rickettsiology, National Institute of Health, Tokyo, Japan
- Dr L.E. Reichert, Jr., Professor and Chairman, Department of Biochemistry, The Albany Medical College of Union University, Albany, NY, USA
- Dr L. Sjodin, Chief, Biological Section, Department of Drugs, National Board of Health and Welfare, Uppsala, Sweden
- Professor Tsou Pang-chu, Chief, Division of Bacterial Vaccine, National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China

### *Representative(s) of other organizations*

#### *International Union of Immunological Societies*

- Dr H. Lowenstein, Protein Laboratory, University of Copenhagen, Copenhagen, Denmark

### *Secretariat*

- Dr D. Bangham, National Institute for Biological Standards and Control, London, England (*Temporary Adviser*)
- Dr D.H. Calam, National Institute for Biological Standards and Control, London, England (*Temporary Adviser*)
- Mr I. Davidson, Head, Biological Products and Standards Department, Central Veterinary Laboratory, Weybridge, Surrey, England (*Temporary Adviser*)
- Dr J. Gerin, Division of Molecular Virology and Immunology, Georgetown University Medical Center, Rockville, MD, USA (*Temporary Adviser*)
- Dr S.L. Jeffcoate, Department of Biochemical Endocrinology, Chelsea Hospital for Women, London, England (*Temporary Adviser*)
- Dr H.W. Krijnen, Director, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands (*Temporary Adviser*)
- Mr P. Lemoine, Institute of Hygiene and Epidemiology, Brussels, Belgium (*Temporary Adviser*)

Mr J. Lyng, Head, Laboratory for Biological Standardization, State Serum  
Institute, Copenhagen, Denmark (*Temporary Adviser*)  
Dr J.C. Petriccioni, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)  
Dr S.N. Saxena, Director, Central Research Institute, Kasauli, India (*Temporary  
Adviser*)  
Dr G.C. Schild, Director, National Institute for Biological Standards and  
Control, London, England (*Temporary Adviser*)  
Dr D. Thomas, National Institute for Biological Standards and Control, London,  
England (*Temporary Adviser*)  
Dr D. Zewdie, National Research Institute of Health, Addis Ababa, Ethiopia  
(*Temporary Adviser*)  
Dr Zhou Zhao Zheng, Shanghai Institute for Biological Products, Shanghai,  
China (*Temporary Adviser*)

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30776](https://www.yunbaogao.cn/report/index/report?reportId=5_30776)

